Epizyme, Inc. (NASDAQ:EPZM) reported Q2 2017 earnings this Morning, coming in at ($0.48) per share, beating Wall Street’s estimates of ($0.54) per Share. Revenue for the quarter came in at $10.00 million missing the streets estimates of $3.95 million
Analyst Coverage For Epizyme, Inc. (NASDAQ:EPZM)
These are 10 Buy Ratings .
The current consensus rating for Epizyme, Inc. (NASDAQ:EPZM) is Buy (Score: 3.00) with a consensus target price of $24.86 , a potential (75.67% upside)Recent Insider Trading for Epizyme, Inc. (NASDAQ:EPZM)
- On 7/24/2017 Peter Tai-Ching Ho, Insider, sold 15,000 with an average share price of $13.44 per share and the total transaction amounting to $201,600.00.
- On 6/30/2017 Andrew E Singer, CFO, sold 3,024 with an average share price of $15.50 per share and the total transaction amounting to $46,872.00.
- On 6/26/2017 Peter Tai-Ching Ho, Insider, sold 15,000 with an average share price of $14.87 per share and the total transaction amounting to $223,050.00.
- On 6/6/2017 Robert A Copeland, Insider, sold 2,500 with an average share price of $13.45 per share and the total transaction amounting to $33,625.00.
- On 5/25/2017 Peter Tai-Ching Ho, Insider, sold 15,000 with an average share price of $16.11 per share and the total transaction amounting to $241,650.00.
- On 5/2/2017 Robert A Copeland, Insider, sold 5,000 with an average share price of $17.44 per share and the total transaction amounting to $87,200.00.
Recent Trading for Epizyme, Inc. (NASDAQ:EPZM) Shares of Epizyme, Inc. closed the previous trading session at 14.15 up +1.70 13.65% with 696,451 shares trading hands.